Applications for:
"Drug Repurposing Opportunities Across Heterogeneous Brain Cancers, with FDA-Approved Drug Moelcules"

Om Prakash, Escorwin Innovations Private Limited, Lucknow-226021, India.
Email: mailbox4op@gmail.com

This framework comprises two custom applications. The first, in-mac, is a profile-generation engine that computes computational bioassay-based activity signatures for small molecule across 15 pathway-relevant components. The second, ReBrain, is a database for broad-spectrum drug-repurposing analytics. It is hypothesized that FDA-approved drugs capable of modulating these pathways could induce therapeutically meaningful shifts in oncogenic network states. This hypothesis suggests opportunities for drug-repurposing across diverse brain cancer types.

Available Applications

2. ReBrain Database

The ReBrain Database provides a structured repository intended to support neurological and brain-related research efforts. The platform enables users to explore curated datasets and reference material in an open-access environment.

Access URL:
https://assay.smallmoles.com/escorwin/rebrain/rebrain.html

Access Status: Free in public domain

1. ‘in-mac’ Profile Generator

The in-mac Profile Generator is an openly accessible analytical tool designed to generate structured profiles for research and exploratory analysis, with demonstrated application in brain cancer–related data interpretation.

Access URL:
https://assay.smallmoles.com/escorwin/inmac/braincancer.html

Access Status: Free in public domain
Public Access-Key: password

Acknowledgement: The author OP would like to express his sincere gratitude to Escorwin Innovations Pvt. Ltd. for providing the infrastructure necessary for the development of the web application. The generous support and commitment to innovation played a crucial role in the successful completion of this work. Institutional manuscript ID is: escorwininnovations/ms/2025/09/02.
Disclaimer: These applications are provided for research purposes. Users are encouraged to apply appropriate application at their end.